Akademik Veri Yönetim Sistemi
Acta Cardiologica, cilt.78, sa.6, ss.665-671, 2023 (SCI-Expanded, Scopus)
Objective: In this study, we aimed to investigate the safety, feasibility and efficacy of Select Secure® lead in a pure paediatric cohort and to present our experience with implantation technique, complications, and acute and midterm performance of the lead. Method: From 2014 to 2020, 42 consecutive paediatric patients underwent a cardiac device implantation with Select Secure® lead system. Patient demographics, implantation technique, and locations, sensing and pacing characteristics, impedances and any complications at implant and follow-up were investigated. Results: The mean age and weight of patients were 11.2 ± 3.5 years and 34.7 ± 14.8 kg, respectively. A total of 78 Select Secure® leads were successfully implanted. All ventricular leads were successfully anchored to the right ventricular midseptum. Implantation procedures were uneventful in all patients. We showed that atrial and ventricular sensing, pacing thresholds, and impedance measurements did not change significantly and that adequate pacing parameters were achieved in our patients during a median follow-up period of 47 months (4 − 68). Atrial and ventricular sensing, pacing thresholds and impedance measurements remained almost the same during the study period. Conclusions: In this study, we found that the Select Secure® transvenous pacing system was safe and feasible in paediatric patients without any major complications and with very stable electrical performance in the acute and midterm period.